Institutional belief · Medicine and public health
Covid-Organics as established COVID-19 prevention and treatment
Madagascar treated Covid-Organics as a preventive and therapeutic COVID-19 remedy and distributed it through state policy before randomized trials had demonstrated that it prevented or treated the disease.
1 episode
Current understanding
Current understanding
A plausible plant ingredient or traditional use does not establish clinical efficacy against COVID-19. Covid-Organics had not been shown in adequately controlled randomized trials to prevent or treat COVID-19 when it was promoted and distributed. Later clinical evaluation was therefore an evidentiary step that should have preceded claims of established therapeutic benefit.
Consequences and human impact
Consequences and human impact
Madagascar moved Covid-Organics from a locally developed preparation into national pandemic policy. Government plans and audits document mass distribution, use in schools and public administration, and incorporation into the COVID response before efficacy had been established in randomized trials. WHO later treated the related CVO+ product as an investigational remedy requiring a Phase III trial.
How the consequences followed
Artemisia and other plants can contain medically useful compounds. The disputed leap was from a preparation's composition and preliminary observations to treating its COVID-19 preventive or therapeutic effect as established.
Covid-Organics entered national pandemic policy and mass distribution
The national emergency plan recorded distribution of masks and Covid-Organics to examination-class pupils
WHO described CVO+ as undergoing Phase III evaluation rather than as an established treatment
Quantitative figures are highlighted only when the cited evidence supports them. The scale of a related catastrophe is not automatically treated as a death toll caused solely by this belief.
Institutional episode
Madagascar
In 2020 Madagascar incorporated Covid-Organics into its COVID-19 response and distributed it widely as a protective and therapeutic remedy. Government emergency-planning and audit material document school and mass distribution and the remedy’s role in public policy. At the time, controlled evidence establishing prevention or treatment was absent. In 2021 WHO described the related CVO+ preparation as requiring Phase III clinical evaluation to determine safety and efficacy.
Institutions
- Presidency of the Republic of Madagascar
- Prime Minister’s Office (Primature de Madagascar)
Documented consequences
- Mass preventive distribution of Covid-Organics through local administrative structures
- Distribution to school pupils and public services
- Government incorporation of an unproven remedy into the national COVID response
- Public therapeutic legitimacy before randomized efficacy evidence was available
Institutional machinery
Covid-Organics became part of the national COVID response rather than remaining a private experimental product. Government planning documents recorded population and school distribution; the Court of Accounts later documented mass distribution and use across public settings while also noting the lack of scientific evidence tying traditional remedies to outcomes. The 2021 shift toward formal Phase III evaluation did not amount to a categorical Malagasy repudiation of the product.
Sources and what they establish
- Plan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar
Official national emergency plan documenting Covid-Organics as part of the response, including distribution with masks to 270,000 pupils in examination classes.
- Audit organisationnel de la gestion de la crise sanitaire liée à la COVID-19 pour l’année 2020Cour des Comptes de Madagascar
Official audit documenting mass CVO distribution through fokontany, public administration and other settings, while noting that no scientific study could establish a direct causal link between traditional remedies and the observed mortality pattern.
- WHO statement on the clinical trial of CVO+ remedyWorld Health Organization Regional Office for Africa
WHO statement describing CVO+ as an investigational remedy undergoing Phase III clinical evaluation and making recommendation contingent on demonstrated safety and efficacy.
Last reviewed: 24/08/2026